Company intelligence / Profile preview
OSE Immunotherapeutics
Nantes, Pays-de-la-Loire, Franceose-immuno.com ↗
- Ownership
- Public · OSE
- Employees
- ~65
- Development stage
- Phase 3
01
Overview
The lead asset Tedopi®, a neoepitope-based therapeutic cancer vaccine activating tumor-specific T-cells, has shown positive Phase III results in second or third-line Non-Small Cell Lung Cancer patients after failure of immune checkpoint inhibitors. Multiple ongoing Phase II trials are evaluating Tedopi in combination therapies across pancreatic, ovarian, and lung cancers with readouts expected through 2025–2026.
Other clinical assets include:
- OSE‑279: Anti-PD1 monoclonal antibody showing positive early-phase data in solid tumors.
- Lusvertikimab/OSE‑127: IL7 receptor antagonist in Phase II trial for ulcerative colitis; also orphan drug designated by EMA for acute lymphoblastic leukemia.
- FR104/VEL101: Anti-CD28 monoclonal antibody partnered with Veloxis Pharmaceuticals; ongoing Phase I/II studies in kidney transplantation.
- BI765063 & BI770371 developed with Boehringer Ingelheim targeting CD47/SIRPα pathway.
AbbVie recently licensed global rights to OSE’s novel pro-resolutive anti-ChemR23 monoclonal antibody program OSE‑230 aimed at resolving chronic inflammation. This partnership includes $48M upfront plus up to $665M milestones
- Therapeutic areas
- GastroenterologyOncologyImmunology
- Modalities
- Neoepitope-based cancer vaccines (e.g., Tedopi)Monoclonal antibodies (e.g., anti-PD1, anti-CD28, anti-ChemR23, IL7 receptor antagonist)
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
AbbVie – exclusive global license agreement for development/commercialization of chronic inflammation candidate OSE‑230Veloxis Pharmaceuticals – co-development of FR104/VLE101 for transplantation indicationsBoehringer Ingelheim – collaboration on anti-SIRPα antibodies BI765063 & BI770371
04
Financials
- Market cap
- $45M
- Total revenue
- $2.9M
- Enterprise value
- $59.2M
Beyond the preview
Go deeper on OSE Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSE Immunotherapeutics.